Future studies should investigate the complex interplay between EFTUD2/PROM1 expression, clinical/histological progression, and therapeutic responses in ccRCC to provide a more complete understanding of their roles in this disease, and larger cohorts are needed to enable robust stratification. Here, EFTUD2 is linked to nonpapillary renal cell carcinoma.